FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012396747> ?p ?o ?g. }

• W2012396747 endingPage "114" @default.
• W2012396747 startingPage "114" @default.
• W2012396747 abstract "According to the World Health Organization, a third of the world’s population is infected with tuberculosis. The disease is responsible for nearly 2 million deaths each year and over 8 million were developing active diseases. Moreover, according to WHO (2000), tuberculosis deaths are estimated to increase to 35 million between 2000-2020. The majority of tuberculosis patients worldwide are still treated with single drugs, or with 2-drug fixed-dose combinations (FDCs). To improve tuberculosis treatment, 2- and 3-drug FDCs were recommended by the World Health Organization (WHO) as part of the DOTS strategy. Since 1999 a 4-drug FDC was included on the WHO Model List of Essential Drugs. Today, FDCs are important tools to further improve the quality of care for people with TB, and accelerate DOTS expansion to reach the global TB control targets. Fixed dose combination TB drugs could simplifies both treatment and management of drug supply, and may prevent the emergence of drug resistance .Prevention of drug resistance is just one of the potential benefits of the use of FDCs. FDCs simplify administration of drugs by reducing the number of pills a patient takes each day and decreasing the risk of incorrect prescriptions. Most tuberculosis patients need only take 3–4 FDCs tablets per day during the intensive phase of treatment, instead of the 15–16 tablets per day that is common with single-drug formulations It is much simpler to explain to patients that they need to take four tablets of the same type and colour, rather than a mixture of tablets of different shapes, colours and sizes. Also, the chance of taking an incomplete combination of drugs is eliminated, since the four essential drugs are combined into one tablet. FDCs are also simpler for care-givers as they minimize the risk of confusion. Finally, drug procurement, in all its components (stock management, shipping, distribution), is simplified by FDCs. Adverse reactions to drugs are not more common if FDCs are used. Nevertheless, whenever side-effects to one or more components in a FDC are suspected, there will be a need to switch to single-drug formulations. Quality, safety and efficacy of FDC drugs are determined by the manufacturing process i.e. by compliance of the manufacturer with the requirements of good manufacturing practices (GMP) and pharmacopoeial specifications. National TB programmes must establish a QA system WHO established a laboratory network that tests the quality of FDCs in the marketplace and registers products upon request from the pharmaceutical industry. (Med J Indones 2003; 12: 114-9) Keywords: fixed dose combination, tuberculosis, treatment" @default.
• W2012396747 created "2016-06-24" @default.
• W2012396747 creator A5008710442 @default.
• W2012396747 date "2003-05-01" @default.
• W2012396747 modified "2023-10-18" @default.
• W2012396747 title "Fixed Dose Combination for TB treatment" @default.
• W2012396747 cites W2047720317 @default.
• W2012396747 cites W2315232969 @default.
• W2012396747 cites W2461259691 @default.
• W2012396747 doi "https://doi.org/10.13181/mji.v12i2.99" @default.
• W2012396747 hasPublicationYear "2003" @default.
• W2012396747 type Work @default.
• W2012396747 sameAs 2012396747 @default.
• W2012396747 citedByCount "0" @default.
• W2012396747 crossrefType "journal-article" @default.
• W2012396747 hasAuthorship W2012396747A5008710442 @default.
• W2012396747 hasBestOaLocation W20123967471 @default.
• W2012396747 hasConcept C142724271 @default.
• W2012396747 hasConcept C177713679 @default.
• W2012396747 hasConcept C2426938 @default.
• W2012396747 hasConcept C2776623344 @default.
• W2012396747 hasConcept C2780035454 @default.
• W2012396747 hasConcept C2781069245 @default.
• W2012396747 hasConcept C2908647359 @default.
• W2012396747 hasConcept C71924100 @default.
• W2012396747 hasConcept C81603835 @default.
• W2012396747 hasConcept C98274493 @default.
• W2012396747 hasConcept C99454951 @default.
• W2012396747 hasConceptScore W2012396747C142724271 @default.
• W2012396747 hasConceptScore W2012396747C177713679 @default.
• W2012396747 hasConceptScore W2012396747C2426938 @default.
• W2012396747 hasConceptScore W2012396747C2776623344 @default.
• W2012396747 hasConceptScore W2012396747C2780035454 @default.
• W2012396747 hasConceptScore W2012396747C2781069245 @default.
• W2012396747 hasConceptScore W2012396747C2908647359 @default.
• W2012396747 hasConceptScore W2012396747C71924100 @default.
• W2012396747 hasConceptScore W2012396747C81603835 @default.
• W2012396747 hasConceptScore W2012396747C98274493 @default.
• W2012396747 hasConceptScore W2012396747C99454951 @default.
• W2012396747 hasLocation W20123967471 @default.
• W2012396747 hasLocation W20123967472 @default.
• W2012396747 hasOpenAccess W2012396747 @default.
• W2012396747 hasPrimaryLocation W20123967471 @default.
• W2012396747 hasRelatedWork W1874805948 @default.
• W2012396747 hasRelatedWork W2342011470 @default.
• W2012396747 hasRelatedWork W2342098968 @default.
• W2012396747 hasRelatedWork W2358383113 @default.
• W2012396747 hasRelatedWork W2360070380 @default.
• W2012396747 hasRelatedWork W2411956962 @default.
• W2012396747 hasRelatedWork W2412999881 @default.
• W2012396747 hasRelatedWork W2415759662 @default.
• W2012396747 hasRelatedWork W2884171184 @default.
• W2012396747 hasRelatedWork W3215265998 @default.
• W2012396747 isParatext "false" @default.
• W2012396747 isRetracted "false" @default.
• W2012396747 magId "2012396747" @default.
• W2012396747 workType "article" @default.